603351 Stock Overview
Nanjing Well Pharmaceutical Group Co.,Ltd. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 603351 from our risk checks.
Nanjing Well Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥24.07 |
52 Week High | CN¥27.73 |
52 Week Low | CN¥17.65 |
Beta | 0.41 |
11 Month Change | -6.12% |
3 Month Change | 18.92% |
1 Year Change | -11.96% |
33 Year Change | -31.03% |
5 Year Change | 9.44% |
Change since IPO | -2.86% |
Recent News & Updates
Recent updates
Shareholder Returns
603351 | CN Chemicals | CN Market | |
---|---|---|---|
7D | -7.3% | -0.9% | -2.1% |
1Y | -12.0% | -5.3% | 2.8% |
Return vs Industry: 603351 underperformed the CN Chemicals industry which returned -5.3% over the past year.
Return vs Market: 603351 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
603351 volatility | |
---|---|
603351 Average Weekly Movement | 6.7% |
Chemicals Industry Average Movement | 8.0% |
Market Average Movement | 8.4% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603351 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603351's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 673 | Renrong Wu | www.well-js.com |
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical auxiliary materials in China. Its pharmaceutical materials include excipients for injectables and non-injectables.
Nanjing Well Pharmaceutical Group Co.,Ltd. Fundamentals Summary
603351 fundamental statistics | |
---|---|
Market cap | CN¥3.26b |
Earnings (TTM) | CN¥146.83m |
Revenue (TTM) | CN¥1.33b |
22.2x
P/E Ratio2.5x
P/S RatioIs 603351 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603351 income statement (TTM) | |
---|---|
Revenue | CN¥1.33b |
Cost of Revenue | CN¥981.02m |
Gross Profit | CN¥346.50m |
Other Expenses | CN¥199.68m |
Earnings | CN¥146.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.08 |
Gross Margin | 26.10% |
Net Profit Margin | 11.06% |
Debt/Equity Ratio | 25.3% |
How did 603351 perform over the long term?
See historical performance and comparison